LLY
Income statement / Annual
Last year (2024), Eli Lilly and Company's total revenue was $45.04 B,
an increase of 32.00% from the previous year.
In 2024, Eli Lilly and Company's net income was $10.59 B.
See Eli Lilly and Company,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$45.04 B |
$34.12 B |
$28.54 B |
$28.32 B |
$24.54 B |
$22.32 B |
$21.49 B |
$19.97 B |
$21.22 B |
$19.96 B |
| Cost of Revenue |
$8.42 B
|
$7.08 B
|
$6.63 B
|
$7.31 B
|
$5.48 B
|
$4.72 B
|
$4.68 B
|
$6.07 B
|
$5.65 B
|
$5.04 B
|
| Gross Profit |
$36.62 B
|
$27.04 B
|
$21.91 B
|
$21.01 B
|
$19.06 B
|
$17.60 B
|
$16.81 B
|
$13.90 B
|
$15.57 B
|
$14.92 B
|
| Gross Profit Ratio |
0.81
|
0.79
|
0.77
|
0.74
|
0.78
|
0.79
|
0.78
|
0.7
|
0.73
|
0.75
|
| Research and Development Expenses |
$10.99 B
|
$9.31 B
|
$7.19 B
|
$6.93 B
|
$6.09 B
|
$5.60 B
|
$5.05 B
|
$5.28 B
|
$5.24 B
|
$4.80 B
|
| General & Administrative Expenses |
$0.00
|
$6.94 B
|
$5.10 B
|
$4.90 B
|
$4.77 B
|
$4.90 B
|
$4.83 B
|
$5.03 B
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$1.34 B
|
$1.24 B
|
$1.10 B
|
$1.10 B
|
$900.00 M
|
$700.00 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$8.59 B
|
$6.94 B
|
$6.44 B
|
$6.14 B
|
$5.87 B
|
$6.21 B
|
$5.73 B
|
$6.59 B
|
$6.33 B
|
$6.53 B
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$7.10 B
|
$0.00
|
$0.00
|
$110.10 M
|
$121.60 M
|
$0.00
|
| Operating Expenses |
$19.58 B
|
$16.25 B
|
$13.63 B
|
$13.46 B
|
$12.21 B
|
$11.81 B
|
$11.03 B
|
$11.87 B
|
$11.70 B
|
$11.33 B
|
| Cost And Expenses |
$28.00 B
|
$27.14 B
|
$20.80 B
|
$21.02 B
|
$18.10 B
|
$16.56 B
|
$17.45 B
|
$16.39 B
|
$17.38 B
|
$16.90 B
|
| Interest Income |
$175.20 M
|
$173.60 M
|
$62.80 M
|
$25.40 M
|
$33.00 M
|
$80.40 M
|
$159.30 M
|
$166.40 M
|
$108.70 M
|
$87.00 M
|
| Interest Expense |
$780.60 M
|
$485.90 M
|
$331.60 M
|
$339.80 M
|
$359.60 M
|
$400.60 M
|
$242.50 M
|
$225.00 M
|
$185.20 M
|
$161.20 M
|
| Depreciation & Amortization |
$1.77 B
|
$1.53 B
|
$1.52 B
|
$1.55 B
|
$1.32 B
|
$1.23 B
|
$1.61 B
|
$1.57 B
|
$1.50 B
|
$1.43 B
|
| EBITDA |
$15.23 B |
$8.57 B |
$8.66 B |
$8.04 B |
$8.91 B |
$6.90 B |
$5.53 B |
$3.99 B |
$5.06 B |
$4.38 B |
| EBITDA Ratio |
0.34
|
0.25
|
0.3
|
0.28
|
0.36
|
0.31
|
0.26
|
0.2
|
0.24
|
0.22
|
| Operating Income Ratio |
0.39
|
0.3
|
0.3
|
0.26
|
0.26
|
0.27
|
0.28
|
0.11
|
0.18
|
0.18
|
| Total Other Income/Expenses Net |
-$4.82 B
|
-$3.77 B
|
-$1.85 B
|
-$1.15 B
|
$788.90 M
|
-$733.50 M
|
-$2.35 B
|
$159.80 M
|
-$497.30 M
|
-$802.10 M
|
| Income Before Tax |
$12.68 B
|
$6.55 B
|
$6.81 B
|
$6.16 B
|
$7.23 B
|
$5.27 B
|
$3.68 B
|
$2.30 B
|
$3.37 B
|
$2.79 B
|
| Income Before Tax Ratio |
0.28
|
0.19
|
0.24
|
0.22
|
0.29
|
0.24
|
0.17
|
0.12
|
0.16
|
0.14
|
| Income Tax Expense |
$2.09 B
|
$1.31 B
|
$561.60 M
|
$573.80 M
|
$1.04 B
|
$628.00 M
|
$529.50 M
|
$2.39 B
|
$636.40 M
|
$381.60 M
|
| Net Income |
$10.59 B
|
$5.24 B
|
$6.24 B
|
$5.58 B
|
$6.19 B
|
$8.32 B
|
$3.23 B
|
-$204.10 M
|
$2.74 B
|
$2.41 B
|
| Net Income Ratio |
0.24
|
0.15
|
0.22
|
0.2
|
0.25
|
0.37
|
0.15
|
-0.01
|
0.13
|
0.12
|
| EPS |
11.76 |
5.83 |
6.93 |
6.15 |
6.47 |
4.98 |
3.14 |
-0.19 |
2.59 |
2.27 |
| EPS Diluted |
11.71 |
5.8 |
6.9 |
6.12 |
6.79 |
4.96 |
3.13 |
-0.19 |
2.58 |
2.26 |
| Weighted Average Shares Out |
$900.61 M
|
$903.52 M
|
$905.04 M
|
$912.04 M
|
$912.18 M
|
$957.53 M
|
$1.03 B
|
$1.05 B
|
$1.06 B
|
$1.06 B
|
| Weighted Average Shares Out Diluted |
$904.06 M
|
$903.28 M
|
$904.62 M
|
$911.68 M
|
$912.51 M
|
$935.68 M
|
$1.03 B
|
$1.05 B
|
$1.06 B
|
$1.07 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
